B细胞淋巴瘤中优越嵌合抗原受体T细胞设计与部署的挑战与解决方案
本文聚焦B细胞淋巴瘤中CAR-T疗法的挑战与解决方案。尽管CAR-T在复发/难治B细胞淋巴瘤中显示显著成功,但共识指南有限,其在治疗范式中的定位仍有争议。作者讨论了抗原逃逸、冷肿瘤微环境、宿主炎症和CAR-T细胞耗竭等障碍,强调即时CAR-T制造和早期T淋巴细胞采集等解决方案,并结合FDA批准三种抗CD3/CD20双特异性抗体(mosunetuzumab、epcoritamab和glofitamab)的证据,提出2024年实用建议。
要点
- CAR-T在复发/难治B细胞淋巴瘤中显示显著成功,但共识指南有限,定位仍有争议。
- 早期CAR-T部署的主要障碍包括抗原逃逸、冷肿瘤微环境、宿主炎症和CAR-T细胞耗竭。
- 解决方案包括即时CAR-T制造和早期T淋巴细胞采集,作者结合FDA批准的双特异性抗体提出2024年实用建议。
核心结论
- CAR-T疗法在复发/难治B细胞淋巴瘤中取得显著成功,但其在治疗范式中的定位仍存争议,共识指南有限。
- 作者讨论了早期CAR-T部署的障碍与解决方案,并结合FDA批准三种抗CD3/CD20双特异性抗体的证据,提出2024年实用建议。
研究设计与样本
- 本文为聚焦综述,讨论CAR-T产品在早期治疗线中推进治疗覆盖的主要障碍。
- 综述回顾了B细胞淋巴瘤早期CAR-T部署的证据基础,并结合FDA批准三种first-in-class抗CD3/CD20双特异性抗体(mosunetuzumab、epcoritamab和glofitamab)进行讨论。
主要发现
- 早期CAR-T部署的障碍包括抗原逃逸、冷肿瘤微环境、宿主炎症和CAR-T细胞耗竭。
- 解决方案包括即时CAR-T制造和早期T淋巴细胞采集。
- 复发/难治B细胞淋巴瘤中CAR-T疗法显示显著成功。
- 侵袭性淋巴瘤后续治疗线中的竞争干预包括新型靶向药物、双特异性抗体和历史悠久的干细胞移植。
- FDA批准了三种first-in-class抗CD3/CD20双特异性抗体:mosunetuzumab、epcoritamab和glofitamab。
临床怎么用
- 作者结合FDA批准三种抗CD3/CD20双特异性抗体的证据,提出2024年实用建议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor-T (CAR-T) therapies represent a major breakthrough in cancer medicine, given the ex vivo-based technology that harnesses the power of one's own immune system. These therapeutics have demonstrated remarkable success for relapsed/refractory B-cell lymphomas. Although more than a decade has passed since the initial introduction of CAR-T therapeutics for patients with leukaemia and lymphoma, there is still significant debate as to where CAR-T therapeutics fit into the management paradigm, as consensus guidelines are limited. Competing interventions deployed in subsequent lines of therapy for aggressive lymphoma include novel targeted agents, bispecific antibodies, and time-honoured stem cell transplant. In this focused review, we discuss the major obstacles to advancing the therapeutic reach for CAR-T products in early lines of therapy. Such barriers include antigen escape, "cold" tumour microenvironments, host inflammation and CAR-T cell exhaustion. We highlight solutions including point-of-care CAR-T manufacturing and early T lymphopheresis. We review the evidence basis for early CAR-T deployment for B-cell lymphomas in light of the recent Food and Drug Administration (FDA) approval of three first-in-class anti-CD3/CD20 bispecific antibodies-mosunetuzumab, epcoritamab and glofitamab. We propose practical recommendations for 2024.
引用
- Gao J, Dahiya S, Patel SA, et al. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas. Br J Haematol. 2023. PMID: 37488074. doi:10.1111/bjh.19001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。